RESUMEN
The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD95 in 15/17 human melanoma cell lines analysed, but complete lack of CD95 ligand (CD95L). Overexpression of CD95 in a tetracycline-inducible expression system enhanced melanoma cell sensitivity to CD95 ligation but was unable to trigger apoptosis by itself. In clear contrast, all melanoma cells tested responded with increased apoptosis to conditional expression of CD95L (2-10-fold), both after transient and after stable transfection. Activation of caspase-8, Bid cleavage, cytochrome c release and caspase-3 activation followed after CD95L induction indicating a functional CD95-signaling cascade. CD95L was also able to enhance the proapoptotic effect of chemotherapeutics applied in parallel. Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L. In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression. Due to these data, transfection of CD95L proofs as a highly efficient tool against melanoma cells in vitro and in vivo, and targeted expression of CD95L may thus represent a suitable strategy for melanoma therapy.
Asunto(s)
Apoptosis/fisiología , Melanoma/patología , Glicoproteínas de Membrana/genética , Trasplante Heterólogo/patología , Receptor fas/fisiología , Animales , Antígenos de Superficie/inmunología , División Celular , Células Cultivadas , Proteína Ligando Fas , Regulación de la Expresión Génica/inmunología , Humanos , Masculino , Melanocitos/citología , Glicoproteínas de Membrana/inmunología , Ratones , Ratones Desnudos , ARN Mensajero/genética , Proteínas Recombinantes/inmunología , Transfección , Células Tumorales CultivadasRESUMEN
Therapy resistance is crucial for the high mortality of melanoma. The death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) bears high potential as a new anticancer agent, as binding to the death receptors TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4) or TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5) triggers apoptosis in most cancer cells. For melanoma, however, only a weak responsiveness of primary cultures was reported, and in particular the role of DR4 was neglected. For evaluating melanoma susceptibility, we studied the functionality of DR4 and DR5 in melanoma cells as well as their expression in vivo. DR5 was consistently expressed in melanoma cell lines, whereas DR4 was found in only 2/7 cell lines. High sensitivity to TRAIL-induced apoptosis was characteristic for DR4-positive melanoma cells, whereas DR4-negative cells showed less and delayed response or were resistant. The use of selective DR4/DR5 blocking antibodies unequivocally proved the prevalent role of DR4 in those melanoma cells, where it was expressed. The significance of these data for the in vivo situation was finally evaluated by immunohistochemistry, which proved pronounced expression of DR4 as well as of DR5 in melanoma primary tumors. Thus, DR4 expression in vivo and the high efficiency of DR4-mediated apoptosis may suggest reassessment of the suitability of TRAIL and especially of DR4-based strategies for melanoma treatment.
Asunto(s)
Antineoplásicos/farmacología , Proteínas Reguladoras de la Apoptosis/farmacología , Melanoma/metabolismo , Glicoproteínas de Membrana/farmacología , Receptores del Factor de Necrosis Tumoral/metabolismo , Neoplasias Cutáneas/metabolismo , Factor de Necrosis Tumoral alfa/farmacología , Anticuerpos Bloqueadores/farmacología , Apoptosis , Línea Celular Tumoral , Resistencia a Antineoplásicos , Humanos , Melanoma/química , Melanoma/patología , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF , Receptores del Factor de Necrosis Tumoral/análisis , Receptores del Factor de Necrosis Tumoral/antagonistas & inhibidores , Neoplasias Cutáneas/química , Neoplasias Cutáneas/patología , Ligando Inductor de Apoptosis Relacionado con TNFRESUMEN
Induction of apoptosis has been demonstrated previously by overexpression of CD95 ligand (CD95L) in cultured human melanoma cells. For in vivo approaches based on CD95L, however, targeted expression is a prerequisite and tyrosinase promoters have been considered for selection. Luciferase reporter gene assays performed for a representative panel of melanoma cell lines characterized by strong (SK-Mel-19), moderate (SK-Mel-13, MeWo), weak (A-375), and missing expression (M-5) of endogenous tyrosinase revealed high tyrosinase promoter activities in SK-Mel-19, SK-Mel-13, and MeWo, but only weak activities in A-375 and M-5 as well as in non-melanoma cell lines. After transfection of a CMV promoter CD95L expression construct, melanoma cells were found highly sensitive, as compared with non-melanoma cells. By applying a tyrosinase promoter CD95L construct, apoptosis was selectively induced in SK-Mel-19, SK-Mel-13, MeWo as well as in A-375, which was characterized by high CD95 surface expression and high sensitivity to agonistic CD95 activation. M5 and non-melanoma cell lines remained uninfluenced. Also, resistance to agonistic CD95 activation seen in MeWo characterized by weak CD95 surface expression was overcome by overexpression of CD95L. Our investigations provide evidence that tyrosinase promoter CD95L constructs may be of value for selective induction of apoptosis in therapeutic strategies for melanoma.
Asunto(s)
Apoptosis/fisiología , Melanoma , Glicoproteínas de Membrana/genética , Monofenol Monooxigenasa/genética , Neoplasias Cutáneas , Caspasas/metabolismo , Línea Celular Tumoral , Proteínas de Unión al ADN/genética , Proteína Ligando Fas , Regulación Neoplásica de la Expresión Génica , Terapia Genética/métodos , Humanos , Luciferasas/genética , Glicoproteínas de Membrana/metabolismo , Factor de Transcripción Asociado a Microftalmía , Regiones Promotoras Genéticas/genética , Factores de Transcripción/genéticaRESUMEN
Nitric oxide is a gaseous messenger involved in the regulation of several physiologic processes in various cell types, including skin cells. Three different nitric oxide synthases (neuronal nitric oxide synthase, endothelial nitric oxide synthase, inducible nitric oxide synthase) have been identified in human cells. For inducible nitric oxide synthase, an inducibility by cytokines and lipopolysaccharides have been found. For murine melanoma cells, a connection between elevated levels of nitric oxide after inducible nitric oxide synthase induction and consequent apoptosis had been described. By northern analysis, we detected inducible nitric oxide synthase mRNA in four of 15 human melanoma cell lines cultured without inducible nitric oxide synthase inducing cytokines. Induction of inducible nitric oxide synthase mRNA by tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides was seen in normal human melanocytes but not in melanoma cell lines. In accordance, inducible nitric oxide synthase protein expression was clearly inducible in cultures of normal melanocytes, whereas in six melanoma cell lines investigated, inducible nitric oxide synthase was found weakly expressed already before treatment with tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides, and its expression was not inducible. The apoptotic rates both in normal melanocytes and in two melanoma cell lines (SK-Mel-19 and O-Mel-2) were increased by treatment with tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides; however, these effects could not be prevented by the specific nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine. These data reveal a clear-cut difference between human melanoma cell lines and cultured normal human melanocytes with respect to inducible nitric oxide synthase inducibility. Although the data do not support the hypothesis that inducible nitric oxide synthase is an important regulator for apoptosis in human melanoma cells, the regulation deficiency found for melanoma cells may be of importance for melanocytic transformation and tumor progression.
Asunto(s)
Antineoplásicos/farmacología , Interferón gamma/farmacología , Melanocitos/enzimología , Melanoma , Óxido Nítrico Sintasa/genética , Factor de Necrosis Tumoral alfa/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Neoplasias de la Mama , Inhibidores Enzimáticos/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Lipopolisacáridos/farmacología , Melanocitos/citología , Nitratos/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II , ARN Mensajero/análisis , Células Tumorales Cultivadas/citología , Células Tumorales Cultivadas/enzimología , omega-N-Metilarginina/farmacologíaRESUMEN
Normal human melanocytes respond to endothelin-1 with induced proliferation and differentiation. Whereas in cultured melanoma cells the predominant endothelin receptor, ET(B)-R, is consistently downregulated, ET(B)-R upregulation was recently reported for melanoma tumors. Contrary to the pro-survival activity described for endothelin in vascular cells, a proapoptotic activity of endothelin-1 has been reported for melanoma cells, in previous studies. We therefore investigated the role of endothelin for melanoma cells with respect to apoptosis and proliferation. Treatment with 10 nM endothelin-1 was a strong mitogenic signal for normal human melanocytes, which responded with a 4-6-fold increase of thymidine incorporation, whereas the response was only 1.2-fold for SK-Mel-19, the melanoma cell line characterized by the highest ET(B)-R expression, and it was even less in other cell lines. Determination of the apoptotic rates revealed that endothelin-1 significantly reduced basic apoptotic rates to 75% both in SK-Mel-19 and in normal melanocytes. After cell synchronization, an antiapoptotic effect of endothelin-1 was seen in five of seven cell lines investigated. In the cell line Bro, which showed no response and which lacks ET(B)-R expression, responsibility could be restored by overexpression of ET(B)-R after stable transfection, indicating that the effectors of the endothelin-1 signal cascade were active in these cells, and that the antiapoptotic effect of endothelin-1 is mediated in a receptor-specific way. This antiapoptotic activity of endothelin for melanoma cells combined with upregulation of endothelin receptors in the tumor may be a crucial step for melanoma progression.
Asunto(s)
Apoptosis/efectos de los fármacos , Endotelina-1/farmacología , Melanocitos/citología , Melanoma , Neoplasias Cutáneas , Apoptosis/fisiología , División Celular/efectos de los fármacos , División Celular/fisiología , Regulación hacia Abajo/fisiología , Endotelina-1/metabolismo , Regulación Neoplásica de la Expresión Génica , Humanos , Melanocitos/efectos de los fármacos , Melanocitos/metabolismo , Receptor de Endotelina B , Receptores de Endotelina/genética , Receptores de Endotelina/metabolismo , Transfección , Células Tumorales CultivadasRESUMEN
13-cis Retinoic acid is rapidly absorbed into cells and exerts its anti-proliferative effect on human sebocytes by specific isomerization to high levels of all-trans retinoic acid and binding the retinoic acid receptors. In this study, we have shown that bovine serum albumin, an extracellular binding protein for 13-cis retinoic acid, plays an important part in the uptake of 13-cis retinoic acid in human sebocytes, its intracellular isomerization to all-trans retinoic acid, and the induction of its anti-proliferative effect. The addition of highly concentrated bovine serum albumin (20 mg per ml) to the serum-free maintenance medium resulted in a rather controlled uptake of constant levels of 13-cis and all-trans retinoic acid into the cells over the 72 h of treatment. As a consequence, significantly reduced and delayed isomerization of 13-cis retinoic acid to all-trans retinoic acid was detected. In parallel experiments, the anti-proliferative activity of 13-cis retinoic acid on SZ95 sebocytes was abrogated by adding 20 mg bovine serum albumin per ml into the serum-free medium. These results indicate a critical function of serum albumin as retinoid-binding protein in reducing the concentration of active retinoids and restricting their biologic effects on human sebocytes.
Asunto(s)
Isotretinoína/farmacocinética , Albúmina Sérica Bovina/farmacología , Piel/citología , Tretinoina/metabolismo , División Celular/efectos de los fármacos , Línea Celular Transformada , Interacciones Farmacológicas , Humanos , Isomerismo , Isotretinoína/química , Piel/metabolismo , Tretinoina/químicaRESUMEN
Increased cell volume, accumulation of lipid droplets in the cytoplasm, and nuclear degeneration are phenomena indicating terminal differentiation of human sebocytes followed by holocrine secretion and cell death. The molecular pathways of natural and induced sebocyte elimination are still unknown, however. In this study, SZ95 sebocytes were found to exhibit DNA fragmentation after a 6 h culture followed by increased lactate dehydrogenase release after 24 h, indicating cell damage. With the help of morphologic studies and using Oil Red detection of cellular lipids, cell enlargement, accumulation of lipid droplets in the cytoplasm, and nuclear fragmentation could be observed under treatment with arachidonic acid. Staurosporine, a potent inhibitor of phospholipid Ca2+-dependent protein kinase, increased externalized phosphatidylserine levels on SZ95 sebocytes, detected by annexin V/propidium iodide flow cytometry, as early as after 1 h, whereas dose-dependent reduction of bcl-2 mRNA and protein expression, enhanced DNA fragmentation, and increased caspase 3 levels, detected by caspase 3 inhibitor/propidium iodide flow cytometry, were found after 6 h of treatment. SZ95 sebocyte death was detected as early as after 6 h of SZ95 sebocyte treatment with high staurosporine concentrations (10(-6)-10(-5) M). 5Alpha-dihydrotestosterone (10(-8)-10(-5) M) did not affect externalized phosphatidylserine levels and DNA fragmentation in SZ95 sebocytes but slightly decreased lactate dehydrogenase cell release. Neither acitretin nor 13-cis retinoic acid (10(-8)-10(-5) M) affected externalized phosphatidylserine levels, DNA fragmentation, and lactate dehydrogenase cell release, despite the increased caspase 3 levels under treatment with 13-cis retinoic acid. The combined staurosporine and 13-cis retinoic acid treatment enhanced DNA fragmentation in SZ95 sebocytes to the same magnitude as in cells only treated with staurosporine. In conclusion, SZ95 sebocytes in vitro undergo apoptosis, which can be enhanced by the terminal differentiation inductor arachidonic acid or by staurosporine and leads to cell death. 5Alpha-dihydrotestosterone inhibits SZ95 sebocyte death without involving apoptotic pathways, and retinoids did not affect the programmed death of human sebocytes. The latter result fits well with the currently reported inability of normal skin cells to undergo apoptosis after treatment with retinoids, in contrast to their malignant counterparts.
Asunto(s)
Fragmentación del ADN/fisiología , Glándulas Sebáceas/citología , Glándulas Sebáceas/fisiología , Ácido Araquidónico/farmacología , Caspasa 3 , Caspasas/metabolismo , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Línea Celular Transformada , Fragmentación del ADN/efectos de los fármacos , Dihidrotestosterona/farmacología , Inhibidores Enzimáticos/farmacología , Expresión Génica , Humanos , Isotretinoína/farmacología , L-Lactato Deshidrogenasa/metabolismo , Fosfatidilserinas/metabolismo , Proteínas Proto-Oncogénicas/análisis , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Mensajero/análisis , Glándulas Sebáceas/química , Estaurosporina/farmacología , Proteína X Asociada a bcl-2RESUMEN
The Bcl-2-related proteins Bcl-X(L) and Bcl-X(S) represent alternative splice products and exert opposite activities in the control of apoptosis, but their significance for melanoma is not yet clear. Applying the tetracycline-inducible expression system Tet-On, we found overexpression of Bcl-X(S) by itself sufficient to induce apoptosis in vitro in stably transfected human melanoma cell lines. Combination with proapoptotic agents such as etoposide, pamidronate, and ceramide resulted in additive proapoptotic effects, whereas Bcl-X(L) protected from apoptosis caused via CD95/Fas stimulation. In nude mice growth of melanoma xenotransplants derived from stably transfected cells was significantly reduced after induction of Bcl-X(S) by doxycycline. Our results indicate that Bcl-X proteins are of major importance for control of apoptosis in malignant melanoma.
Asunto(s)
Apoptosis/fisiología , Melanoma/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/fisiología , Animales , Apoptosis/efectos de los fármacos , Núcleo Celular/ultraestructura , Cromatina/ultraestructura , Células Clonales , Doxiciclina/farmacología , Femenino , Humanos , Melanocitos/citología , Melanocitos/metabolismo , Melanoma/genética , Melanoma/patología , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transfección , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto , Proteína bcl-X , Receptor fas/farmacologíaRESUMEN
We examined the biological effects of the ceramide analogues (1S,2R)-2-N-myristoylamino-1-phenyl-1-propanol (D-e-MAPP) and (1R,2R)-2-N-myristoylamino-1-(4-nitrophenyl)-1,3-propandiol (D-NMAPPD) on human HaCaT keratinocytes and human melanoma cells. We could demonstrate that D-e-MAPP and D-NMAPPD are able to suppress acid ceramidase activity. The elevation of the endogenous level of ceramide is followed by induction of apoptosis and suppression of proliferation in HaCaT keratinocytes. Moreover, we recently identified a group of human melanoma cell populations which are heterogeneously susceptible to C2-ceramide-mediated apoptosis. Studies with these melanoma cells revealed correlation between ceramide-mediated apoptosis and D-NMAPPD-induced apoptosis, confirming the effect of this inhibitor on ceramide signaling in human melanoma cells. These findings suggest ceramidase inhibitors as a potential new therapeutical class of antiproliferative and cytostatic drugs.
Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Apoptosis/efectos de los fármacos , Apoptosis/genética , Inhibidores Enzimáticos/farmacología , Genes bcl-2 , Melanoma/tratamiento farmacológico , Melanoma/patología , Ceramidasa Ácida , División Celular/efectos de los fármacos , Línea Celular , Ceramidasas , Ceramidas/metabolismo , Ceramidas/farmacología , Expresión Génica , Humanos , Queratinocitos/citología , Queratinocitos/efectos de los fármacos , Queratinocitos/enzimología , Melanoma/enzimología , Melanoma/genética , Miristatos/farmacología , Propanolaminas/farmacología , Células Tumorales CultivadasRESUMEN
Protein kinase C (PKC), a calcium and phospholipid-dependent kinase, has been implicated in carcinogenesis of melanocytic cells. However, its role in melanoma cell growth remains controversial. We therefore investigated the growth dependence of PKC isozyme expression in human normal melanocytes and melanoma cells. Logarithmic and stationary growth phases in culture were clearly distinguished by nuclear cell staining with the proliferation marker Ki-67. PKC-beta I and -beta II were expressed exclusively in normal melanocytes but not in melanoma cells, whereas PKC-gamma was not found in any of the cultures studied. Low PKC-delta, -epsilon and -zeta mRNA levels were detected by RT-PCR in proliferating melanoma cells and higher in confluent non-proliferating cells, whereas levels of PKC-alpha mRNA remained rather stable. Subcellular fractionation and immunoblotting revealed accordingly low expression of PKC-alpha, -delta, -epsilon, and -zeta in the logarithmic growth phase of melanoma cells, with subsequent increase of expression and of membrane association in the stationary phase. Only weak differences were detected between the growth phases in normal melanocytes for the respective PKC isozymes, except for membrane-associated PKC-beta I and -beta II which were clearly elevated in confluent melanocyte cultures. These data suggest that certain PKC isozymes are involved in the intracellular signalling that regulates melanoma cell proliferation, and may function as suppressors of tumour cell growth.
Asunto(s)
División Celular/fisiología , Isoenzimas/metabolismo , Melanocitos/enzimología , Melanoma/enzimología , Proteína Quinasa C/metabolismo , Western Blotting , Células Cultivadas , Citosol , Regulación de la Expresión Génica/fisiología , Humanos , Isoenzimas/genética , Antígeno Ki-67/metabolismo , Melanocitos/efectos de los fármacos , Melanoma/patología , Proteína Quinasa C/genética , Proteína Quinasa C beta , ARN/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The initial steps of melanocytic dysfunction in vitiligo are hitherto not well understood. The aim of the present study was to examine the sequence of early events that occur in melanocytes after autologous minigrafting in patients with vitiligo, depending on their clinical response. Six patients with non-segmental widespread vitiligo were included in the study. Specimens of vitiliginous lesions were used as preoperative controls and sequential punch biopsies were taken from the grafted areas on days 14, 17, 21 and 28 after minigrafting. Immunohistochemical stains using the MoAbs HMB-45, CD4, CD8, ICAM-1, and LFA-1 were performed in all biopsies and the labelled cells were counted by a digital image analyser. Results obtained show that in vitiligo patients not responding to minigrafting, significant numbers of cytotoxic T-lymphocytes and LFA-1 positive infiltrating cells occur in early phases (p < 0.05), suggesting that a cell-mediated immune response takes place towards the grafted melanocytes. Possibly this cell-mediated mechanism causing unresponsiveness to minigrafts may also play a role in the pathogenesis of vitiligo.
Asunto(s)
Trasplante de Piel , Piel/metabolismo , Vitíligo/metabolismo , Adulto , Antígenos de Neoplasias/análisis , Antígenos CD4/análisis , Antígenos CD8/análisis , Femenino , Humanos , Inmunohistoquímica , Molécula 1 de Adhesión Intercelular/análisis , Leucocitos/química , Antígeno-1 Asociado a Función de Linfocito/análisis , Masculino , Melanocitos/química , Antígenos Específicos del Melanoma , Proteínas de Neoplasias/análisis , Piel/inmunología , Piel/patología , Vitíligo/inmunología , Vitíligo/patología , Vitíligo/cirugíaRESUMEN
The importance of apoptosis in hair follicle cycling is still not clearly understood, however, its regulation in follicular keratinocytes (FK) during bulb regression (catagen) may be essential for hair regrowth. So far, the control of FK apoptosis remains unknown. In this study, the anti-inflammatory cytokine IL-4 was found to induce apoptosis dose and time dependently in cultured human FK, in contrast to other agents known to inhibit hair growth such as IL-1alpha, IL-1beta, TNFalpha and TGFbeta, as shown by DNA fragmentation. On the other hand, cytokines reported to be involved in hair follicle cycling including IL-4 were not able to induce apoptosis in dermal papilla cells (DPC), in contrast to staurosporine. This PKC inhibitor revealed dose-dependent apoptotic signals not only for DPC but also for FK in vitro. In further experiments the expression of apoptosis regulating proteins, possibly involved in catagen formation, was analyzed in FK and DPC. However, no striking difference in RNA expression was seen in either cell population under culture conditions and after incubation with IL-4. We conclude, therefore, that IL-4 mediated apoptosis may participate in regulating catagen formation in the hair follicle, acting selectively on cultured FK and being independent of bcl-2 and bax expression.
Asunto(s)
Apoptosis/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Fibroblastos/fisiología , Interleucina-4/farmacología , Queratinocitos/efectos de los fármacos , Queratinocitos/fisiología , Apoptosis/fisiología , Secuencia de Bases , Células Cultivadas , Citocinas/farmacología , Dermis/citología , Dermis/efectos de los fármacos , Factor de Crecimiento Epidérmico/farmacología , Femenino , Folículo Piloso/citología , Folículo Piloso/efectos de los fármacos , Humanos , Etiquetado Corte-Fin in Situ , Masculino , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sensibilidad y Especificidad , Estaurosporina/farmacologíaAsunto(s)
Anticuerpos Anticitoplasma de Neutrófilos/sangre , Anticuerpos Monoclonales/efectos adversos , Antineoplásicos/efectos adversos , Paniculitis Nodular no Supurativa/inducido químicamente , Paniculitis Nodular no Supurativa/inmunología , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Antineoplásicos/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , TrastuzumabAsunto(s)
Anticonvulsivantes/efectos adversos , Trastorno Bipolar/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Hipersensibilidad a las Drogas/etiología , Trastornos Psicóticos/tratamiento farmacológico , Ácido Valproico/efectos adversos , Anticonvulsivantes/uso terapéutico , Erupciones por Medicamentos/diagnóstico , Hipersensibilidad a las Drogas/diagnóstico , Quimioterapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Pruebas del Parche , Factores de Riesgo , Ácido Valproico/uso terapéuticoAsunto(s)
Acné Vulgar/tratamiento farmacológico , Hidroxiurea/análogos & derivados , Hidroxiurea/uso terapéutico , Inhibidores de la Lipooxigenasa/uso terapéutico , Acné Vulgar/patología , Administración Oral , Adolescente , Femenino , Humanos , Hidroxiurea/administración & dosificación , Inhibidores de la Lipooxigenasa/administración & dosificación , Masculino , Proyectos PilotoRESUMEN
During periods of smoking, patients with Behçet's disease have less oral aphthae than in abstinence. To elucidate this observation, human keratinocytes and dermal microvascular endothelial cells (HMEC-1) were incubated with serum of 20 patients with Behçet's disease and 20 healthy controls for 4 hours. Maximum non-toxic concentrations were determined and the cells were further treated with 6 microM nicotine, 3.3% cigarette smoke extract (CES), 100 microM biochanin A, and 6.25/12.5 microM pyrrolidine dithiocarbamate alone and in combinations for 24 hours. Serum IL-8 levels of patients were significantly lower than those of controls. However, after 4 hours incubation with patients' sera, IL-8 release by both cell types was markedly increased when compared with the corresponding serum levels. The levels of IL-6 and vascular endothelial growth factor (VEGF) release were after 4 hours similar with the corresponding levels in serum. IL-1 was not detected. Nicotine significantly decreased IL-8 and -6 release by HMEC-1 maintained in both patients' and controls' sera, but only IL-6 release by keratinocytes maintained in patients' sera. VEGF release by both cells was markedly increased after nicotine treatment in either serum. CES significantly decreased IL-8 release and increased production of VEGF in keratinocytes maintained in patients' serum. The phytoestrogen biochanin A alone and in combination with nicotine further decreased the secretion of IL-8, -6, and VEGF in all experimental settings. Our data support a specific anti-inflammatory effect of nicotine on keratinocytes and endothelial cells maintained in the serum of patients with Behçet's disease. Moreover, biochanin A is likely to exhibit similar and even more profound results than nicotine.